Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human FDPS Anticorps:
anti-Rat (Rattus) FDPS Anticorps:
anti-Mouse (Murine) FDPS Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal FDPS Primary Antibody pour IHC (p), WB - ABIN389054
Strausberg, Feingold, Grouse, Derge, Klausner, Collins, Wagner, Shenmen, Schuler, Altschul, Zeeberg, Buetow, Schaefer, Bhat, Hopkins, Jordan, Moore, Max, Wang, Hsieh, Diatchenko, Marusina, Farmer et al.: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. ... dans Proceedings of the National Academy of Sciences of the United States of America 2002
Show all 8 Pubmed References
Human Polyclonal FDPS Primary Antibody pour IF, IHC (p) - ABIN1882080
Nomura, Miyajima, Sazuka, Tanaka, Kawarabayasi, Sato, Nagase, Seki, Ishikawa, Tabata et al.: Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature ... dans DNA research : an international journal for rapid publication of reports on genes and genomes 1995
Show all 4 Pubmed References
mitochondrial targeting of FPS may be widespread among eukaryotes
Farnesyl diphosphate synthase (FPPS) of the dipteran Drosophila melanogaster has been cloned and its catalytic properties have been assessed.
FPPS mediates TGF-beta1 (Montrer TGFB1 Anticorps)-induced lung cancer cell invasion and epithelial-to-mesenchymal transition via the RhoA (Montrer RHOA Anticorps)/Rock1 (Montrer ROCK1 Anticorps) pathway.
Crystallographic and thermodynamic characterization of phenylaminopyridine bisphosphonates binding to human farnesyl pyrophosphate synthase
These results are consistent with the previously proposed hypothesis that the allosteric pocket of human FPPS, located near the active site, plays a feed-back regulatory role for this enzyme.
our study indicated that DR patients have higher VEGF (Montrer VEGFA Anticorps) levels than diabetic patients without retinopathy, and -2578A/C (rs699947) and +405C/G (rs2010963) may be important factors in determining serum VEGF (Montrer VEGFA Anticorps) levels.
Results suggest that polymorphisms of the FDPS gene may influence the bone response to drugs targeting the mevalonate pathway, like statins.
A co-crystal structure of human farnesyl pyrophosphate synthase in complex with a bisphosphonate and two molecules of inorganic phosphate.
The results identify new classes of FPPS inhibitors, diterpenoids and sesquiterpenoids, that bind to the IPP (Montrer IPP Anticorps) site and may be of interest as anticancer and antiinfective drug leads.
These observations suggest that an increase in the expression of endogenous FPPS could confer at least partial resistance to the pharmacological effect of N-BP drugs such as ZOL in vivo
LRP5 (Montrer LRP5 Anticorps) and FDPS loci age-specifically affect skeletal traits in healthy fertile women.
Data indicate compounds represent a new structural class of farnesyl pyrophosphate synthase (hFPPS) inhibitors and suggest a development of therapeutics.
Overexpression of FPPS aggravates myocardial ischemia/reperfusion injury in mice.
Farnesyl pyrophosphate synthase (FPPS) may function as a potent regulator in myocardial remodelling. The FPPS-regulated signalling pathway is relevant to the pathological changes in cardiac hypertrophy and heart failure.
identified a single putative direct repeat 4 (DR4 (Montrer HLADRB4 Anticorps)) LXR (Montrer NR1H3 Anticorps) response element in the FPS (Montrer FES Anticorps) promoter isolated from immortalized murine astrocyte P11 (Montrer S100A10 Anticorps)-5 cells
This gene encodes an enzyme that catalyzes the production of geranyl pyrophosphate and farnesyl pyrophosphate from isopentenyl pyrophosphate and dimethylallyl pyrophosphate. The resulting product, farnesyl pyrophosphate, is a key intermediate in cholesterol and sterol biosynthesis, a substrate for protein farnesylation and geranylgeranylation, and a ligand or agonist for certain hormone receptors and growth receptors. Drugs that inhibit this enzyme prevent the post-translational modifications of small GTPases and have been used to treat diseases related to bone resorption. Multiple pseudogenes have been found on chromosomes 1, 7, 14, 15, 21 and X. Multiple transcript variants encoding different isoforms have been found for this gene.
farnesyl pyrophosphate synthase
, farnesyl diphosphate synthase
, farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase)
, farnesyl pyrophosphate synthetase
, Farnesyl pyrophosphate synthetase
, (2E,6E)-farnesyl diphosphate synthase
, FPP synthase
, FPP synthetase
, farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase
, CR 39
, cholesterol-regulated 39 kDa protein
, farnesyl diphosphate synthetase
, testis-specific farnesyl pyrophosphate synthetase
, 6E)-farnesyl diphosphate synthase
, geranylgeranyl-diphosphate synthase